

706735 The Journal of

HOSPITAL PHARMACY

FORMERLY THE "PUBLIC PHARMACIST"

OFFICIAL ORGAN OF THE GUILD OF PUBLIC PHARMACISTS

PUBLISHED MONTHLY

Gentacin® topical

rapid results in bacterial skin infections

Gentacin

Cream and Ointment 15g

Impetigo

Burns

Decubitus ulcers

Folliculitis

Varicose ulcers

Decubitus ulcers

Gentacin HC

Cream and Ointment 15g

Otitis externa


Intertrigo
(severe nappy rash
in infants)

Eczemas

Eczematous
periphery of ulcers

Further information
available on request from
British Schering Limited
Nicholas Laboratories
Limited
Slough Buckinghamshire

Gentacin brand of
Gentamicin Sulphate



This material was copied
at the NLS and may be
subject to copyright.

Factors Influencing Drug Stability in Intravenous Infusions

JOHN JACOBS, M.Pharm., F.P.S.

*Deputy Director of Pharmacy Services, Meyer de Rothschild
Hadassah University Hospital, Jerusalem, Israel*

SUMMARY

In order to preserve the activity of drugs given by infusion, many factors must be considered. The infusion fluid must be chosen with care so that the presence of any electrolyte or sugar or the pH of the solution does not provide an unsuitable medium for the added drugs.

Where drugs are inherently unstable small infusion flasks may be used or the drug may be added to the last few hundred millilitres of the infusion. Additional drugs should be added only when no incompatibility occurs. With very unstable drugs, injection into the infusion tubing may be undertaken. Where a chemical incompatibility occurs between two drugs, they should be given in separate infusion bottles.

THE traditional role of the pharmacist in the hospital environment is undergoing rapid change. He has recently taken on clinical responsibility by leaving the pharmacy and in conjunction with physicians and nurses has attempted to bring safer and more effective procedures into practice in the everyday work of drug distribution and medication administration. A short time ago it was acceptable to think that the pharmacist's responsibility ended when a drug was dispensed from the pharmacy. This is no longer true and the pharmacist is often present in the ward to advise on drug administration. Advice is frequently sought on the preparation and administration of intravenous solutions. This is a complex field in which the careful consideration of drug properties and infusion stability is required to ensure that patients receive a drug mixture which will bring about the required therapeutic effect. If care is not taken in compounding infusions a patient may receive an infusion which may not be beneficial and may even be harmful.


There is an important area of investigational work to be covered in the determination of stability of intravenous solutions

and the results and conclusions of the survey described here are the first stage in this work.

During a two-month survey, the use of intravenous drugs was observed in 17 departments of the Hadassah University Hospital. In the majority of the departments surveyed, drugs were added to the infusion fluid. A single drug was most frequently added, with occasional mixtures of two to four drugs concurrently administered in one infusion bottle. Five or even six drug combinations were not unknown. This reflects the physician's dilemma in attempting to administer a large number of drugs in an efficient manner when the oral route cannot be used. Some patients suffering from weight loss and emaciation cannot tolerate intramuscular injections and the unnecessary pain of multiple injections each day can be avoided when the intravenous route of administration is employed.

The survey showed that 56 drugs and 8 infusion fluids were commonly given. Among the drugs used there were 13 antibiotics, 11 sympathomimetic and cardiovascular agents, 2 antihistamines, 6 vitamins and 5 hormones.

New Product Announcement



Dalacin C

Upjohn introduces Dalacin C
a new antibiotic
effective in a wide range of
Gram-positive infections.

Introductory date 17th November 1969

Availability:



150 mg. Capsule (clindamycin) (maroon/lavender)



75 mg. Paediatric Capsule (clindamycin) (lavender/
lavender)

PRICE TO CHEMIST:	150 mg. Capsules:	16s	100s	500s
	75 mg. Paediatric Capsules:	28/-	168/-	830/-
		15/-	90/-	444/6

Your usual wholesaler will have supplies, but in case of difficulty
please contact us direct.

Full product information available on request

Upjohn

Registered Trademark Dalacin 1169 501 UK

UPJOHN LIMITED • FLEMING WAY • CRAWLEY • SUSSEX

Only in a few of the world's largest hospitals does the pharmacy department provide an intravenous additive service which prepares and dispenses individual infusion bottles containing the necessary drugs prescribed by the physician. One such unique and comprehensive intravenous solution service is provided by the Ohio State University Hospitals, and intravenous infusions containing added drugs are prepared under direct pharmaceutical supervision and are available on demand day and night.¹

Whether the pharmacy provides such a service or not, pharmacists should have knowledge of the stability factors involved when a drug is added to an infusion fluid. They can then advise the nursing staff how the infusion can be prepared and safely given to the patient without decomposition and loss of activity, or the formation of toxic products.

The factors influencing drug stability in intravenous infusion include:

Time of preparation: The interval between the preparation and the administration of the infusion should be minimal. In the event of contamination this does not allow excessive multiplication of bacteria, reduces drug decomposition and, perhaps even more important, the possibility that the wrong patient may receive the infusion due to a change in nursing shift. This interval should never be longer than one hour. Infusions of drugs not used soon after preparation should be rejected. They must not be refrigerated and used at a later stage.

Duration of infusion: The survey showed that the duration of infusion was commonly from $\frac{1}{2}$ hour to 12 hours, and occasionally 24 hours. Bacterial contamination would be more likely in infusions administered over long periods and many drugs decompose within a few hours. It is suggested that infusion time should not

exceed 12 hours per flask and preferably 8 hours per flask.

pH of the solution: Many drugs decompose rapidly when added to a solution of unsuitable pH. (See table 1) Dextrose infusions are the common cause of stability problems since they are almost always acid in reaction. The lower pharmacopoeial limit is pH 3.5. In solutions of very low pH, methicillin sodium may be decomposed and free methicillin acid precipitated in the infusion flask. With other drugs, e.g. ampicillin, heparin, etc., no precipitate may be formed, but much of the drugs' activity is rapidly lost.

Electrolytes: The presence of electrolytes in the infusion, especially in high concentration, may cause drug decomposition or precipitation. (See table 2)

Sugars and polysaccharides: The presence of apparently innocuous sugars may cause instability. Sulphadiazine sodium injection has a pH of about 10.5. When this is added to dextrose solutions of pH 4.4, the pH of the solution is raised to 8.5 and a deep yellow colour develops over some hours.

Physical state of the infusion: Not all infusions are simple solutions. Blood is a coarse suspension, mannitol in the high concentration usually employed for forced diuresis is a supersaturated solution and emulsions of fats are also used, e.g. Intralipid.[®] In some cases room temperature can influence solubility. Infusion fluids may have to be warmed to 37°C to ensure that the solids are completely dissolved and that the solution is homogenous, e.g. 25% mannitol. Supersaturated solutions can be readily crystallised out and it is recommended that no additions be made to mannitol, inulin, etc., in these concentrations. Fat emulsions may be "cracked" and separation of the phases or enlargement of the globule size may occur if drugs are added

Table 1

DRUG STABILITY IN SOLUTION ACCORDING TO pH

<i>Drug</i>	<i>Stability characteristics</i>
Aminophylline	Unstable in neutral or acid solution.
Ampicillin sodium	Loses 10% activity in 4 hours in dextrose or dextrose-saline. Preferable to administer in saline or Ringers solution.
Amylobarbitone sodium	Should not be added to solutions with a pH below 8.0. May be given in saline.
Benzylpenicillin sodium	Unstable in highly acid solutions.
Carbenicillin sodium	Unstable in alkaline solutions. Given in saline, dextrose or dextrose-saline during 6 hours or less.
Heparin	Rapidly inactivated in solutions with a pH below 6.0. Should not be infused in dextrose or dextrose-saline over a long period.
Methicillin sodium	Acid solutions may cause cloudiness or precipitation. Check dextrose solutions frequently for clarity during infusion. Administer during 6-8 hours.
Novobiocin sodium	Must not be added to dextrose infusions. Administer in saline or Ringers solution.
Sulphadiazine sodium	Incompatible with laevulose and very acid dextrose infusions may cause precipitation. May be administered in normal saline.

pH of common infusion fluids (B.P.* or U.S.P.** limits)

Ammonium chloride	4.0 - 6.0**
Dextran 40 in 5% dextrose (Rheomacrodex in dextrose)	3.5 - 6.5*
Dextran 40 in Normal saline (Rheomacrodex in saline)	4.0 - 7.0*
Dextrose 5%	3.5 - 6.5*
Hartmann's solution	5.0 - 7.0*
	6.0 - 7.5**
Mannitol 10%	4.5 - 7.0*
Protein hydrolysate	5.0 - 7.0**
Sodium chloride	4.5 - 7.0**
Sodium chloride 0.18% with Dextrose 4.3%	3.5 - 6.5*
Sodium lactate 1/6 molar	5.0 - 7.0*

indiscriminately. The makers recommend that apart from the cautious addition of heparin no other drug be added to infusion bottles of fat emulsions. These emulsions may however be given concurrently with saline or dextrose solutions provided that they are administered through a Y—tube placed just before the needle.

Drug reaction with containers, closures or the infusion set: A few drugs may be

absorbed by rubber stoppers, e.g. those containing phenolic groupings, and glass itself has been reported to adsorb insulin from solution.² Mercaptomerin must be injected through rustless needles and must not come into contact with aluminium fittings.³ The use of non-neutral glass containers, or surface-treated glass containers in which the film has become worn or scratched, may liberate alkali into

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.